Ernexa Therapeutics Inc. Convertible Notes Payable, Noncurrent
Ernexa Therapeutics Inc. (ERNA) had Convertible Notes Payable, Noncurrent of $32.04 million as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:ConvertibleLongTermNotesPayable · last filed 2025-03-12
- 2024-09-30: Convertible Notes Payable, Noncurrent $32.04M.
- 2024-06-30: Convertible Notes Payable, Noncurrent $8.89M.
- 2024-03-31: Convertible Notes Payable, Noncurrent $8.01M.
- 2023-12-31: Convertible Notes Payable, Noncurrent $6.77M.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2024-09-30 | $32.04M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $8.89M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $8.01M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $6.77M 10-K · filed 2025-03-12 |
| 2023-09-30 | $3.45M 10-Q · filed 2023-11-13 |
| 2023-07-14 | $8.70M 10-Q · filed 2023-11-13 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |